The 2026 FIFA World Cup, hosted jointly by the United States, Canada, and Mexico, will be the largest tournament in the competition’s history, setting the stage for an event of unprecedented scale and global attention. Amid the excitement surrounding the tournament, FIFA works extensively behind the scenes not only to deliver a successful event, but also to safeguard players’ health and uphold the integrity of the sport. A central component of this effort is ensuring that all athletes compete on a level playing field through a comprehensive anti-doping program. This commitment is reflected in FIFA’s close partnership with the World Anti-Doping Agency (WADA), the independent international body responsible for leading and coordinating the global fight against doping in sport.
FIFA’s Anti-Doping Regulations are fully aligned with the World Anti-Doping Code and its associated International Standards, which establish the testing procedures, laboratory requirements, and results-management processes that govern anti-doping programs globally.
One of the most important elements of this framework is WADA’s laboratory accreditation program, which ensures that all participating laboratories maintain consistent scientific and analytical standards. The American Association for Laboratory Accreditation (A2LA) plays a significant role in this process by accrediting laboratories to ISO/IEC 17025, the international standard that verifies technical competence, quality management systems, and the production of reliable and traceable analytical results. Working in collaboration with WADA, A2LA also accredits laboratories to the International Standard for Laboratories (ISL), which expands upon ISO/IEC 17025 by incorporating sport-specific analytical requirements, enhanced chain-of-custody procedures, and strict reporting obligations. As a result, all samples collected under FIFA authority are analyzed exclusively by WADA-accredited laboratories that comply with both ISO/IEC 17025 and ISL requirements.
Within the United States, WADA has designated two laboratories: the UCLA Olympic Analytical Laboratory and the Sports Medicine Research and Testing Laboratory (SMRTL). According to FIFA’s Anti-Doping Report for January 2024 through July 2025, these laboratories analyzed a combined total of 1,111 samples for FIFA. While the FIFA World Cup and other major international tournaments generate significant testing volume, these laboratories routinely support anti-doping programs across a wide range of sporting events throughout the year. As a result, managing large-scale testing programs falls well within the normal scope of their operations.
Major sporting events such as the World Cup require these laboratories to maintain high-quality analytical performance while operating under accelerated turnaround times associated with a fast-paced international tournament. To meet these demands, both laboratories maintain robust Quality Management Systems (QMS) designed to ensure consistent analytical accuracy, reliability, and efficiency under increased operational pressure. The accreditation process is essential to this objective, as both technical competence and quality management systems are routinely assessed against stringent WADA and ISO requirements. Rapid and reliable testing is critical to ensuring that potential anti-doping rule violations are identified efficiently without disrupting tournament operations. As the scale of the FIFA World Cup continues to expand, the role of accredited anti-doping laboratories becomes increasingly important in safeguarding athlete health, ensuring fair competition, and preserving public confidence in the integrity of international sport.
FIFA Anti-Doping Report January 2024 – July 2025
https://digitalhub.fifa.com/m/2d8cca121682a7f7/original/Anti-doping-Report-2024-2025.pdf